Snapshot from Aug 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Serina SER-252 trial completes Cohort 1
Business clinical trial milestone

Serina SER-252 trial completes Cohort 1

Analysis based on 7 articles · First reported Jul 09, 2026 · Last updated Jul 23, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive trial progress may boost investor confidence in Serina's pipeline and POZ platform, potentially increasing the company's stock price. However, as an early-stage clinical milestone, the impact is limited until further efficacy and safety data emerge.

biotechnology pharmaceuticals
Event Summary

Serina Therapeutics, a clinical-stage biotechnology company, announced the completion of sentinel dosing and subsequent full enrollment and dosing of Cohort 1 in its Phase 1b registrational trial of SER-252 for advanced Parkinson's disease. The independent Safety Monitoring Committee reviewed initial safety data and recommended continued dosing. The milestone was achieved ahead of the company's prior guidance of end of Q3 2026. The trial is a randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures. Sites are in the United States and Australia, with plans to expand to South Korea and Taiwan. Serina's POZ platform technology is also licensed to Pfizer for lipid nanoparticle drug delivery.

Key Actions
80 Serina Therapeutics completed enrollment and dosing
70 Serina Therapeutics completed sentinel dosing
Entities Involved
priv
Serina Therapeutics
Serina achieved a key operational milestone in its lead clinical program, advancing SER-252 toward potential registration. The company's stock may see positive sentiment from the ahead-of-schedule progress.
Importance 100.0 Sentiment 30.0
per
Steve Ledger
As CEO, Steve Ledger announced the milestone and expressed confidence in the trial execution. His leadership is positively highlighted.
Importance 30.0 Sentiment 10.0
cnt
United States
Clinical trial sites in the US are part of the study, but no direct impact on the country.
Importance 20.0 Sentiment 0.0
cnt
Australia
Clinical trial sites in Australia are part of the study, but no direct impact on the country.
Importance 20.0 Sentiment 0.0
stock
Pfizer
Pfizer has a non-exclusive license to Serina's POZ technology for LNP delivery, but this event does not directly affect Pfizer.
Importance 10.0 Sentiment 0.0
cnt
South Korea
Planned future trial sites in South Korea may benefit from clinical research activity, but no current impact.
Importance 10.0 Sentiment 0.0
cnt
Taiwan
Planned future trial sites in Taiwan may benefit from clinical research activity, but no current impact.
Importance 10.0 Sentiment 0.0
ngo
HudsonAlpha Institute of Biotechnology
Serina is headquartered on the HudsonAlpha campus, but the institute is not directly involved in the trial.
Importance 5.0 Sentiment 0.0
Relationships
United States related ↔ Australia
United States related ↔ Pfizer
United States related ↔ South Korea
United States security partner ↔ Taiwan The United States acts as Taiwan's primary security partner and arms supplier, maintaining robust economic ties and semi
Australia related ↔ South Korea
Australia related ↔ Taiwan
South Korea related ↔ Taiwan
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.